Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Sandeep Bhapkar"'
Autor:
Yatin Mehta, K. C. Mishra, Yashesh Paliwal, Pradeep Rangappa, Sharmili Sinha, Sandeep Bhapkar
Publikováno v:
Critical Care Research and Practice, Vol 2022 (2022)
Levonadifloxacin (intravenous) and its oral prodrug alalevonadifloxacin are broad-spectrum antibacterial agents developed for the treatment of difficult-to-treat infections caused by multidrug-resistant Gram-positive bacteria, especially methicillin-
Externí odkaz:
https://doaj.org/article/260b1f33b29643b084b14d8fffc58eac
Publikováno v:
IHJ Cardiovascular Case Reports, Vol 2, Iss 3, Pp 166-168 (2018)
Non-vitamin K antagonist oral anticoagulants are effective for prevention of stroke in atrial fibrillation (AF) but management of emergency situations in some patients receiving these drugs can be challenging. Idarucizumab, a specific reversal agent
Externí odkaz:
https://doaj.org/article/f878d7cf2b67405d8306d50ae6fcdb62
Autor:
Dr. Prahlad Prabhudesai, Dr. Ashish Jain, Dr. Prashant Borade, Dr. Abhijeet Khandelwal, Kapil Mehta, Dr. Sandeep Bhapkar, Dr. Bini Thampi, Dr. Pramit Sonone
Publikováno v:
International Journal of Innovative Research in Medical Science. 6:919-925
Background: Community-acquired bacterial pneumonia (CABP) remains a global public health threat and is a leading cause of hospitalization and infection-linked mortality. Levonadifloxacin is a novel benzoquinolizine antibiotic with a broad-spectrum ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::327a819ec01493a77eaacff6d0897883
https://doi.org/10.23958/ijirms/vol06-i12/1295
https://doi.org/10.23958/ijirms/vol06-i12/1295
Autor:
Kapil D Mehta, Jai B Sharma, Ashok Anand, Pavan K Reddy N, Pramod Kadam, Khokan Debnath, Sandeep Bhapkar, Bini M Thampi
Publikováno v:
Cureus. 14(4)
Background Antimicrobial resistance by bacteria poses a substantial threat to the success in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Levonadifloxacin is a novel benzoquinolizine subclass of quinolone which has a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b845de84f2a979f9189896e0cc264c25
https://pubmed.ncbi.nlm.nih.gov/35602817
https://pubmed.ncbi.nlm.nih.gov/35602817
Autor:
Nilan T. Jacob, Rajesh Reddy Sannareddy, Sonesh Kalra, Rajesh Reddy Chenna, Sandeep Bhapkar, Sandeep Nayani
Publikováno v:
Journal of Stroke Medicine. 2:155-157
Non-vitamin K antagonist oral anticoagulants have provided an optimization of management of patients in the prevention of stroke in nonvalvular atrial fibrillation. The lack of an effective reversal agent has remained a challenge to these agents’ w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::469898eb15a2dc99873bd3b28ead655d
https://doi.org/10.1177/2516608519864761
https://doi.org/10.1177/2516608519864761
Publikováno v:
IHJ Cardiovascular Case Reports (CVCR). 2:166-168
Non-vitamin K antagonist oral anticoagulants are effective for prevention of stroke in atrial fibrillation (AF) but management of emergency situations in some patients receiving these drugs can be challenging. Idarucizumab, a specific reversal agent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0de2ac1a9fcdbdf3a5b0aa7a56e95b38
https://doi.org/10.1016/j.ihjccr.2018.08.013
https://doi.org/10.1016/j.ihjccr.2018.08.013